Acorda reports net income of $12.4 million for third quarter 2010 Acorda Therapeutics, Inc. today announced its monetary results for the 3rd quarter of 2010.D., Acorda Therapeutics’ President and CEO. We are gratified by the opinions from patients and doctors, and are proud that AMPYRA offers unique benefits to people with MS.6 million. Acorda began shipping AMPYRA to specialty pharmacies on March 1, 2010 and recognized product sales of $3.4 million in the first quarter and $29.7 million in the second quarter. Product sales of AMPYRA are recognized pursuing shipment of the product from the Company’s distribution service to its network of specialty pharmacies.‘The role of age in disease is normally underestimated,’ described Dr. Barzilai. ‘Aging is usually a major factor for the development of most adult onset illnesses. If we have the ability to determine the biology of ageing, then we are able to look for ways to drive back it and increase health span, or living disease-free even into advanced later years. Our analysis – in both the Institute and our fresh Center – is ultimately aimed at finding treatments to prevent or slow this technique.’ Einstein’s Center will be run under the auspices of the Institute, enhancing the institute’s currently robust research component.